Interaction of ruthenium(II) and ruthenium(III) ions with 5-methyl-1,2,4-triazolo[1,5-α] pyrimidin-7{4H)-one
PBN-AR
Instytucja
Narodowy Instytut Leków
Informacje podstawowe
Główny język publikacji
en
Czasopismo
Polyhedron
ISSN
0277-5387
EISSN
Wydawca
PERGAMON-ELSEVIER SCIENCE LTD
URL
Rok publikacji
2014
Numer zeszytu
Strony od-do
410-415
Numer tomu
67
Link do pełnego tekstu
Identyfikator DOI
Liczba arkuszy
Autorzy
(liczba autorów: 4)
Pozostali autorzy
+ 3
Słowa kluczowe
pl
kompleks rutenu(II)
kompleks rutenu(III)
EPR
Ruthenium(II) complex
Ruthenium(III) complex
15N
NMR
EPR
X-ray
Triazolopyrimidine
Streszczenia
Język
en
Treść
Ru(II) and Ru(III) complexes with 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one (HmtpO) of the formula cis-[RuCl 2 (dmso) 3 (HmtpO)] (1) and trans-[RuCl 4 (dmso)(H 2 mtpO)]·4H 2 O (2) have been synthesized and characterized using different spectroscopic techniques (IR, 1 H– 15 N HMBC, 1 H– 13 C HSQC, 1 H– 13 C HMBC and EPR). Spectroscopic studies reveal a monodentate coordination of the heterocycle ligand (HmtpO) via N3 to the ruthenium(II) and ruthenium(III) ions. In addition, the X-ray crystal structure was determined for complex (2). The compound crystallized in the triclinic group P1¯. The asymmetric unit of the structure consists of two complex molecules (2a and 2b) and 8 water molecules. The equatorial positions are occupied by four chloride ions, while the N3 bonded, protonated H 2 mtpO + and S-bonded dmso ligands are located in axial positions. Complex (1) has been screened for in vitro cytotoxicity against two human cells: non-small cell lung carcinoma (A549) and breast cancer (T47D). The ruthenium(II) complex was found to be less active than cisplatinum.
Inne
System-identifier
PX-56b45b298106eb71826df538